Nanobiotix stock plummets 22.5% in one month and threatens a key support level
The Paris-based biotech is declining this Monday in an SBF 120 that is nonetheless in slight positive territory, extending a difficult sequence that began several weeks ago. The decline brings the stock close to its 200-day moving average, the only moving support floor still below the current price.
A 3% decline that extends a downtrend spanning several weeks
Nanobiotix is down 3.08% to €28.94 during the session, while the SBF 120 is up 0.76%. This performance diverging from the index trend places the stock among the SBF 120's biggest decliners. Over one week, the decline reaches 7.54%, and over one month it peaks at 22.62%, which contrasts sharply with an annual performance still in exceptional territory at +196.2%. The technical configuration reflects this selling pressure.
The price is trading 13% below the 20-day MA at €33.27 and nearly 14.5% below the 50-day MA at €33.84, two levels that form a double ceiling difficult to break in the short term. Only the 200-day MA at €28.24 remains below the price, with a gap of 2.48%: the stock is approaching it dangerously, especially as the RSI at 38 reflects persistent selling pressure without yet tipping into outright oversold territory. Technical support is established at €29.86 (the level of the last close), already breached during the session.
A market context unfavorable to biotechs sensitive to long-term rates
The session is taking place in a tense macro environment. The Fed, ECB, and Bank of Japan raised their benchmark rates during the past week, while the Bank of England held steady while warning that further increases remain possible. Central bankers cite sustained rises in oil and gas prices linked to the conflict between the United States and Iran. At the Fed, 16 of 18 committee members anticipate at least one additional quarter-point increase by year-end. This coordinated monetary tightening mechanically weighs on valuations of growth and clinical research companies, which depend on favorable access to long-term financing.
For Nanobiotix, whose model is based on developing its NBTXR3 radiosensitizer with partner Johnson & Johnson (Janssen), this context of elevated rates comes on top of digesting clinical data published on September 14, 2026, which had not been sufficient to stem the stock decline. During the session, sector comparables remain spared: Sanofi declines only 0.01% and Eurofins Scientific gains 0.92%. The 200-day MA at €28.24, now less than 3% away, constitutes the next reference level observable in the current trajectory.
